Biohaven (NYSE:BHVN) Current Accrued Expense

: $10.87 Mil (As of Sep. 2022)

View and export this data going back to 2022. Start your Free Trial

Biohaven's Current Accrued Expense for the quarter that ended in Sep. 2022 was $10.87 Mil.

Biohaven's quarterly Current Accrued Expense increased from Dec. 2021 ($24.05 Mil) to Jun. 2022 ($47.02 Mil) but then declined from Jun. 2022 ($47.02 Mil) to Sep. 2022 ($10.87 Mil).

Biohaven's annual Current Accrued Expense increased from . 20 ($0.00 Mil) to Dec. 2020 ($17.84 Mil) and increased from Dec. 2020 ($17.84 Mil) to Dec. 2021 ($24.05 Mil).

Biohaven Current Accrued Expense Historical Data

The historical data trend for Biohaven's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data

Trend

Dec20

Dec21

Current Accrued Expense

17.84

24.05

Biohaven Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22
Current Accrued Expense		-	-	24.05	47.02	10.87

Biohaven Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Biohaven Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Biohaven's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven (NYSE:BHVN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.

Executives

Robert J Hugin	director	C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Gregory Bailey	director	4 A CHESHAM STREET LONDON X0 SW1X8DT
Kimberly Gentile	officer: SVP, Clinical Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
John W Childs	director	111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Vlad Coric	director, officer: Chief Executive Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Irina Antonijevic	director	215 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten	officer: Chief Financial Officer	215 CHURCH STREET NEW HAVEN CT 06510
Kishan Mehta	director	540 WEST 49TH STREET UNIT# PH1N NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd.	10 percent owner	215 CHURCH STREET NEW HAVEN CT 06510
Bruce Car	officer: Chief Scientific Officer	AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139